Ceralasertib (AZD6738) is a potent and selective orally active ATR kinase inhibitor with a reported IC50 of 1 nM. It demonstrates antitumor activity in preclinical research, being utilized in both in vitro and in vivo studies to investigate DNA damage response pathways and combination therapies in oncology.